Stammdaten
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Unternehmen & Branche
| Name | Citius Pharmaceuticals, Inc. |
|---|---|
| Ticker | CTXR |
| CIK | 0001506251 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 7,4 Mio. USD |
| Beta | 1,38 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 3,944,111 | -0.38 | 140,391,730 | 79,958,162 | |
| 2025-03-31 | 10-Q | -11,511,505 | -1.27 | 121,481,411 | 60,659,412 | |
| 2024-12-31 | 10-Q | -10,281,246 | -1.30 | 120,703,457 | 65,408,079 | |
| 2024-06-30 | 10-Q | -10,573,336 | -1.57 | 97,090,579 | 85,683,899 | |
| 2024-03-31 | 10-Q | -8,544,154 | -1.34 | 90,711,369 | 79,366,571 | |
| 2023-12-31 | 10-Q | 9,231,185 | -1.45 | 97,399,822 | 84,734,254 | |
| 2023-09-30 | 10-K | -32,542,912 | -5.57 | 103,611,150 | 90,831,108 | |
| 2023-06-30 | 10-Q | -8,479,332 | -0.06 | 110,404,835 | 97,699,787 | |
| 2023-03-31 | 10-Q | -10,526,025 | -0.07 | 104,240,826 | 91,206,138 | |
| 2022-12-31 | 10-Q | -3,593,645 | -0.02 | 111,705,221 | 100,433,301 | |
| 2022-09-30 | 10-K | -33,640,646 | -0.23 | 113,999,302 | 102,825,865 | |
| 2022-06-30 | 10-Q | -8,863,632 | -0.06 | 120,315,795 | 109,735,610 | |
| 2022-03-31 | 10-Q | -7,561,054 | -0.05 | 127,785,970 | 117,595,565 | |
| 2021-12-31 | 10-Q | -9,225,220 | -0.06 | 137,516,076 | 123,957,621 | |
| 2021-09-30 | 10-K | -23,054,434 | -0.23 | 142,429,059 | 132,182,353 | |
| 2021-06-30 | 10-Q | -5,824,008 | -0.05 | 146,592,848 | 136,681,573 | |
| 2021-03-31 | 10-Q | -4,122,432 | 134,666,413 | 125,161,786 | ||
| 2020-12-31 | 10-Q | -8,146,909 | 35,311,781 | |||
| 2020-09-30 | 10-K | -17,548,085 | 43,773,655 | 33,670,668 | ||
| 2020-06-30 | 10-Q | -4,680,118 | 38,399,718 | 28,742,062 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.